This week in therapeutics




Licensing status

Publication and contact information


Multiple myeloma (MM)

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; NCA; CD66c)

Cell culture studies suggest inhibiting CEACAM6 could help improve immunotherapy treatments for MM. In the study,
T cells cultured with MM cells showed comparable reactivity and cytotoxicity to T cells cultured alone. In the cell lines and in patient samples, an anti-CEACAM6 mAb or small interfering RNA against the antigen restored T cell reactivity and cytotoxicity against MM cells, whereas control mAbs or siRNA did not. Next steps could include evaluating an anti-CEACAM6 mAb in combination with T cell immunotherapy in MM models.
At least three companies have CEACAM6-targeting antibodies in preclinical development to treat various solid cancers.

SciBX 6(19); doi:10.1038/scibx.2013.467
Published online May 16, 2013

Patent and licensing status unavailable

Witzens-Harig, M. et al. Blood; published online April 19, 2013;
Contact: Philipp Beckhove, German Cancer Research Center, Heidelberg, Germany